Skip to main content
. 2019 Feb 13;32(7):929–942. doi: 10.1038/s41379-019-0210-3

Fig. 9.

Fig. 9

a Faint cytoplasmic staining for PD-L1 in breast carcinoma. This is not considered to be true positive staining (22C3). b Nuclear staining for PD-L1. This is not considered to represent positive staining in any scoring systems (22C3)